Head and Neck Cancer Drug Pipeline Analysis Report 2025

As per the National Cancer Institute estimations, around 71,100 people will be diagnosed with some type of head and neck cancer in the United States in 2024. Out of this, about 16,110 people will die from these diseases. Men are more susceptible to developing the condition when compared to females. Around 69% of the individuals diagnosed with oral cavity or pharynx cancer can survive 5 years or longer from their diagnosis. As a result, there is a high emphasis on providing effective drug alternatives to improve the quality of life of patients across the globe.

Report Coverage

The Head and Neck Cancer Drug Pipeline Insight Report by the publisher gives comprehensive insights into head and neck cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for head and neck cancer. The head and neck cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The head and neck cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with head and neck cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to head and neck cancer.

Head and Neck Cancer Drug Pipeline Outlook

Head and neck cancer comprises various types of cancer in the larynx, throat, lips, mouth, nose, or salivary glands. Since it includes multiple indications, the diagnosis can be difficult. Early symptoms mimic common conditions like a sore throat or cold. As a result, the susceptibility to overlook the disease is higher. Prolonged consumption of tobacco and alcohol is amongst the leading causes of head and neck cancer. Around 70% to 80% of these cancers are associated with tobacco use.

There are various types of head and neck cancers. Oral cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer and salivary gland cancer are among some common types.

In January 2024, the United States Food and Drug Administration (FDA) approved toripalimab (Loqtorzi), the first immunotherapy drug for nasopharyngeal carcinoma (NPC) treatment. The approval was based on the results of two clinical trials and was sponsored by Shanghai Junshi Biosciences. The trials were conducted across Asia as the prevalence of NPC is considerably higher in the region as compared to other parts of the world.

In May 2024, Petosemtamab also received the FDA's Breakthrough Therapy designation for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treatment in patients. This bispecific antibody is currently under phase 1/2 trial, wherein the overall response rate (ORR) is around 37%.

The head and neck cancer clinical assessment covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.

Head and Neck Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of head and neck cancer drug candidates based on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Route of Administration

The head and neck cancer report assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Head and Neck Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II trials cover a major share of the total clinical trials conducted, with approximately 2700 plus head and neck cancer emerging drugs in the pipeline.

Head and Neck Cancer- Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under head and neck cancer pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to analysis, the parenteral route holds a significant market share based on the route of administration.

Head and Neck Cancer Clinical Trials Assessment - Competitive Dynamics

The report for the head and neck cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed head and neck cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in head and neck cancer clinical trials:

• AstraZeneca PLC.
• GSK plc.
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co., Ltd.
• Orient Europharma Co., Ltd.
• Merck & Co., Inc.
• Sanofi S.A.
• Others

Head and Neck Cancer - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of head and neck cancer clinical trial drugs.

Cabozantinib and Nivolumab

The combination of these two immunotherapies is being evaluated in the BiCaZo study. The phase 2 trial study intends to identify the positive as well as negative effects of squamous head and neck cancer. Cabozantinib can stop tumor growth while Nivolumab can stimulate the immune system against cancer.

Tadalafil and Pembrolizumab

Currently in a phase 2 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), this combination of drugs is under investigation to be in combination. The evaluation also involves checking its efficacy as a combination against the effect of PS-1 inhibition alone.

Ado-Trastuzumab Emtansine

This drug is being investigated to treat HER2-positive salivary gland cancer. The primary objective is to determine if the drug shows improved progression-free survival (PFS) against docetaxel plus trastuzumab (TH) while the secondary objectives include overall response rate comparison. Sponsored by the National Cancer Institute, this drug is under phase 2 trial tests.

M3814 (Peposertib)

As a part of the phase 1 interventional study, this head and neck cancer drug candidate is under investigation to be added to the radiation therapy regime for advanced treatment. The primary objective of the study includes determining the recommended phase 2 dosage for M3814 (Peposertib) when administered in combination with intensity-modulated radiation therapy (IMRT). In addition, the evaluation for its tolerability and safety is also in order.

Reasons To Buy This Report

The Head and Neck Cancer Drug Report provides a strategic overview of the latest and future landscape of treatments for head and neck cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within head and neck cancer pipeline insights.

Key Questions Answered in the Head and Neck Cancer - Pipeline Assessment Report

• What is the current landscape of head and neck cancer pipeline drugs?
• Which companies/institutions are developing head and neck cancer therapeutic drugs?
• How many phase II drugs are currently present in head and neck cancer pipeline drugs?
• Which company is leading the head and neck cancer pipeline development activities?
• What is the current head and neck cancer commercial assessment?
• What are the opportunities and challenges present in the head and neck cancer drug pipeline landscape?
• What is the efficacy and safety profile of head and neck cancer pipeline drugs?
• Which companies/institutions are involved in head and neck cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in head and neck cancer?

This product will be delivered within 3-5 business days.